Vaccinex Inc VCNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VCNX is a good fit for your portfolio.
News
-
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
-
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
-
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
-
Vaccinex, Inc. Announces Reverse Stock Split
-
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
Trading Information
- Previous Close Price
- $5.93
- Day Range
- $5.62–6.74
- 52-Week Range
- $4.43–100.80
- Bid/Ask
- $5.70 / $6.38
- Market Cap
- $9.24 Mil
- Volume/Avg
- 12,339 / 14,596
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.82
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 40
- Website
- https://www.vaccinex.com
Valuation
|
Metric
|
VCNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4.82 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VCNX
|
|---|---|
Quick Ratio | 0.42 |
Current Ratio | 0.57 |
Interest Coverage | −20,250.00 |
Quick Ratio
VCNX
Profitability
|
Metric
|
VCNX
|
|---|---|
Return on Assets (Normalized) | −398.97% |
Return on Equity (Normalized) | −8,924.75% |
Return on Invested Capital (Normalized) | −3,129.65% |
Return on Assets
VCNX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qtvpbtck | Kkzzn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bcxmsqms | Zrxzmb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bjymgzqr | Hxmpkd | $97.8 Bil | |
MRNA
| Moderna Inc | Lqfhvdmf | Lnw | $38.8 Bil | |
ARGX
| argenx SE ADR | Pkfryhmr | Jclj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Pvxhcfvl | Kmlh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pvsvpmmb | Tnvsj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mpnfdknt | Xntmz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wppytsgjr | Fdrkzk | $12.5 Bil | |
INCY
| Incyte Corp | Vggfpktv | Nprwc | $11.5 Bil |